Table 4.
Model | Activity | Plant part/compd. | Study design | Mechanism | Ref. |
---|---|---|---|---|---|
Bacterial | Antimicrobial and antivirulence activities against Pseudomonas aeruginosa | PPE (Aqueous extract) |
P. aeruginosa collected from burn wound cultures | ↓Bacterial gelatinase activity by 40.28±2.35%; ↓Lecithinase activity by 53.84±4.89%; MIC= 1.4 mg/ml |
(118) |
Cellular | Protection against skin photoaging induced by UVB irradiation | Rind, seed, and fruit (methanol extracts) | Normal human dermal fibroblasts; Irradiated with UVB (170 mJ/cm2) for 1 min. | ↑Procollagen type I and MMP-1 expression (especially by rind extract); ↑Collagen synthesis |
(119) |
Cellular | Inhibition of melanin content | Fruit (ethanol extract) |
Melan-a melanocyte cells; Melanin inhibition assay; Fruit extract standardized to 20% punicalagin; at concentrations of 50 µg/ml and 100 µg/ml | ↓Melanin content by 40% (50 µg/ml) and 60% (100 µg/ml) | (120) |
Cellular | Anti-tyrosinase activity | Rind (methanol extract) |
Murine melanoma B16 F0 cells; Positive control=Kojic acid (1%); Extract concentrations (200–500 mg/ml) | Tyrosinase inhibition at 500 μg/ml= 82.3±5% | (121) |
Cellular | Inhibition of melanin production | Fruit (ethanol extract) |
Testing Salvia hispanica (chia) seed extract and P. granatum fruit extract (20% punicalagin), in combination or alone; Melanin inhibition assay: Melan-a cells, positive control=phenylthiourea 60 μg/ml; Tyrosinase enzyme assay: enzyme extracted from B16 melanoma cells, positive control=kojic acid; Melanogenesis-related gene expression (RT-PCR) analysis: Melan-a cells, positive control=ascorbic acid-2-glucoside | ↓Melanin content (1:1 ratio of the combination of extracts showed maximum efficacy); Not effectively inhibiting tyrosinase activity; ↓Tyrosine, Tyrp1 and Mc1r expression |
(122) |
Cellular | Protection against oxidative stress | Pomegranate extract | Human keratinocyte HaCaT cells treated with extract for 24 hr; Methylglyoxal-induced cytotoxicity, | ↓Methylglyoxal-DNA adducts, reactive oxygen species; ↑Cell adhesion, migration, and wound healing capacity |
(123) |
Animal | Chemopreventive agent against skin cancer | Seed oil | Female CD1 mice; Skin cancer initiated with topical exposure of 7,12-dimethylbenzanthracene and with biweekly promotion using 12-O-tetradecanoylphorbol-13-acetate (TPA); Pretreated with 5% pomegranate seed oil | ↓Tumor incidence (P=0.05) and multiplicity; ↓TPA-induced ornithine decarboxylase (ODC) activity (17% reduction) |
(124) |
Animal | Cutaneous wound healing | Pomegranate peel polyphenols (PPP) gel | Adult alloxan-induced diabetic Wistar rats; Polyphenol mass fraction in PPP gel=30%; | ↓Wound closure; ↑Fibroblast infiltration, collagen regeneration, vascularization, and epithelialization in the wound area; ↑Hydroxyproline, NO production, and NO synthase activities; ↑Transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) expressions |
(119) |
Animal | Wound healing activity | PPE (methanol extract) |
Wistar rats; Water-soluble gel of extract; Negative control=no gel, positive control=blank gel, commercial preparation=silver sulfadiazine; Treatment with 2.5% and 5.0% gel | ↑Wound healing by 55.8% at 2.5% and 59.5% at 5.0% (on day 15); ↑Hydroxyproline content up to 34.5% (2.5%), and 48.5% (5.0%) compared with the negative control; ↑Hydroxyproline 24.1% (2.5%) and 38.0% (5.0%) compared with the positive control |
(125) |
Animal | Wound healing activity | Male abortive flowers (ethanol extract) |
Male Wistar rats; reference standard (nitrofurazone ointment); topical treatment (extract ointment 200 mg/kg/day); Control (simple ointment); 16 days | ↓Wound size, inflammation cells, collagen fibers, and re-epithelization | (126) |
Animal | Anti-inflammatory activity on the skin | Rind (aqueous extract); Total pomegranate tannins (TPT) |
Porcine skin mounted in Franz diffusion cells; Test solutions (1 ml): pomegranate rind extract (PRE) (consisted of 20% w/w punicalagin), PRE + ZnSO4, ZnSO4, TPT, tannin-free fraction (TFF) and control=phthalate buffer pH 4.5; Analysis of COX-2 by SDS PAGE and western blotting and Immunohistochemical (IHC) | TPT and PRE and PRE + ZnSO4: ↓COX-2 expression (after 6 hr and up to 24 hr); No anti-inflammatory activity by ZnSO4 and TFF and control |
(127) |
Animal | Antiaging effect on UVB-induced skin | Pomegranate juice concentrated powder (PCP) | Female SKH‑1 hairless mice; 6 groups: Intact vehicle control‑unexposed; UVB control‑UVB exposed (mice received vehicle control and UVB exposure); PCS 2 ml/kg ‑UVB exposed; PCP 100 mg/kg‑UVB exposed; PCP 200 mg/kg‑UVB exposed; and PCP 400 mg/kg‑UVB exposed; UVB irradiation three times a week for 15 weeks at 0.18 J/cm2; PCS (contained 2.31 mg/g ellagic acid) | Anti-apoptotic effects; Skin matrix metalloproteinase activity inhibition; ↓Wrinkles induced by photoaging; ↑Skin water contents, collagen type I, and hyaluronan contents; ↓IL‑1β; Inhibition of glutathione depletion |
(128) |
Animal | Wound healing activity | Whole fruit extract standardized with 40% ellagic acid | Male albino rats (Rattus norvegicus); Treatment of incised wounds with topical ointment of pomegranate extract at 2.5, 5, and 7.5% concentrations or Betadine® ointment, twice a day for 7 and 14 days | ↑Wound healing in the application of 7.5% pomegranate extract ointment for 14 days; ↑Collagen deposition; ↓Polymorphonuclear neutrophils infiltration in wound area; ↑Angiogenesis |
(129) |
Animal | Wound healing activity | PPE | Inbred Sprague–Dawley male rats; excision wound model; Control group: petroleum jelly, experimental group: PPE (100 mg/kg) +petroleum jelly, standard group: mupirocin ointment (100 mg/kg); 15 days | Wound contraction of 95% (P<0.01) by day 15 in the experimental group; ↑Hydroxyproline content (P<0.05) |
(130) |
Animal | Anti-psoriasis activity | Punicalagin | Male BALB/c mice (6–8 weeks of age), imiquimod (IMQ)-induced psoriasis; Five groups: Control group, IMQ group, IMQ + DEX group (DEX, dexamethasone cream, positive drug for psoriasis), IMQ + Vehicle group, IMQ + PUN group (25 mg/kg PUN) | Inhibiting NF-κB-mediated IL-1β transcription and caspase-1-regulated IL-1β secretion | (131) |
Clinical | Anti-aging activity | Arils (methanol extract) |
12 human volunteers aged from 35 to 60 y/o, divided into 2 groups, 2 times daily topical application for a month, one group received a placebo | ↓Free radicals | (132) |
Clinical | Anti-aging activity | Fermented pomegranate extract | Double-blind, 35–55y/o, 40 healthy subjects, half on placebo, drink 50 ml daily; Another 40 subjects, half on placebo, apply 3 ml serum over their face 2 times daily for 4 weeks | ↓Free radicals; ↑Skin moisture, brightness, and elasticity |
(133) |
Clinical | Skin lightening activity | PPE | Split-face, randomized, double-blind, placebo-controlled test of 30 subjects divided into 2 groups; Applied the preparation on half of their face | ↓Free radicals; Tyrosinase and TRP-2 inhibition |
(134) |
Clinical | Protection against radiation-induced skin and mucosal changes | Whole fruit extract | Prospective, clinical, double-blind, case-control study; 60 patients (30 cases and 30 controls) undergoing radiotherapy for head and neck cancer; 12 months; 2 capsules/day for 6–7 weeks; each capsule containing 300 mg extract (40% polyphenols and 27% punicalagin) | ↓Severity of radiation-induced mucositis and dermatitis (P<0.0001) | (135) |
Clinical | Prevention or improvement of skin changes associated with striae | Seed oil | An interventional, nonrandomized study; 20 healthy females; 21–48 years old: 10 with striae albae at the hip level and 10 with no stretchmarks; Measurements of skin hydration level, skin elasticity, and thickness of the dermis at the beginning and after 3 and 6 weeks; Application of oil-in-water cream containing plants once daily | ↑Dermis thickness, hydration, and elasticity values. | (136) |
Clinical | Reduce photodamage from UVB irradiation | POMx® (Pomegranate extract); PJ |
A parallel, three-arm, open-label RCT; n=72, female, 30–45 years, with Fitzpatrick skin type II-IV, 3 groups: 1–1000 mg of pomegranate extract (PomX), 2- oz of PJ, 3- placebo; 12 weeks; determination of minimal erythema dose (MED) and melanin index by cutometer; | ↑MED; ↓Melanin formation |
(137) |
Clinical | Improvements in several biophysical properties, wrinkles, and shifts in the skin microbiome | Pomella® (Pomegranate extract) |
Prospective, double-blind placebo-controlled study, healthy males and females aged 25–55 years; 4 weeks; BTBP 3D Clarity Pro® wrinkle assessment, SkinColorCatch® facial erythema index, and melanin index assessment | ↓Wrinkle severity (P<0.01), forehead sebum excretion rate (P=0.14), facial transepidermal water loss (P<0.05) | (138) |